Minimal Residual Disease (MRD) Testing is a type of In Vitro Diagnostics (IVD) used to detect the presence of cancer cells in a patient's body. It is used to monitor the effectiveness of cancer treatments and to detect the recurrence of cancer. MRD testing is typically performed on a sample of bone marrow or peripheral blood, and can detect cancer cells at levels as low as one in a million. It is used to detect the presence of cancer cells in patients with leukemia, lymphoma, and multiple myeloma. MRD testing is a rapidly growing market, driven by the increasing prevalence of cancer and the need for more accurate and sensitive diagnostic tests. The development of new technologies, such as next-generation sequencing and flow cytometry, has enabled more accurate and sensitive MRD testing. Companies in the MRD testing market include Abbott, Agilent Technologies, Bio-Rad Laboratories, Becton Dickinson, and Roche Diagnostics. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
